BullFrog AI receives Australian patent for mebendazole prodrugs including BF-223

BullFrog AI Holdings, Inc.

Australian Patent No. 2019216757 issued for novel prodrugs of mebendazole to treat cancers.
Follows U.S. Patent No. 11,712,435 issued July 2023; additional territories expected.
Patented compounds show improved solubility and oral bioavailability versus parent mebendazole.
BF-223, a key pipeline asset, previously showed anticancer activity in a glioblastoma animal model.
CEO Vin Singh says patent strengthens IP protection and supports partnering strategy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.